Read by QxMD icon Read

Sodium glucose transporters

Gizella Aboagye, Stefania Dall'Olio, Francesco Tassone, Martina Zappaterra, Salvatore Carpino, Leonardo Nanni Costa
Despite the increasing interest in the welfare of animals during transport, very little is known on the response of local pig breeds to the transport procedures. This study aims to compare the effect of short journey on behaviour, blood parameters, and meat quality traits in 51 Apulo-Calabrese and 52 crossbreed [Duroc × (Landrace × Large White)] pigs. All the animals were blood sampled five days before delivery (basal condition) and at exsanguination for the analysis of creatine kinase, cortisol, glucose, lactate, albumin, albumin/globulin, total protein, urea, creatinine, aspartate aminotransferase (AST), alanine aminotransferase, alkaline phosphate, sodium, and potassium...
October 10, 2018: Animals: An Open Access Journal From MDPI
Amit Ganguly, Sherin U Devaskar
We examined the effect of a high-fat diet (HFD) vs. control diet (CD) upon pregestational and gestational wild-type (wt) and glucose transporter (glut)3 heterozygous (glut3+/- ) female mice and observed an increase in pregestational body weights, white adiposity (wt > glut3+/- ), circulating cholesterol, and high-density lipoproteins, with glucose intolerance in both genotypes. The HFD-exposed offspring displayed reduced birth weight with catch up to CD-fed in wt vs. an increased birth weight persisting as such at weaning by day 21 in glut3+/- mice...
September 13, 2018: Journal of Nutritional Biochemistry
Mentor Sopjani, Lulzim Millaku, Dashnor Nebija, Merita Emini, Miribane Dermaku-Sopjani, Arleta Rifati-Nixha
Glycogen synthase kinase-3 (GSK-3) is a highly evolutionarily conserved and ubiquitously expressed serine/threonine kinase, an enzyme protein profoundly specific for glycogen synthase (GS). GSK-3 is involved in various cellular functions and physiological processes, including cell proliferation, differentiation, motility, and survival as well as glycogen metabolism, protein synthesis, and apoptosis. There are two isoforms of human GSK-3 (named GSK-3α and GSK-3β) encoded by two distinct genes. Recently, GSK-3β has been reported to function as a powerful regulator of various transport processes across the cell membrane...
October 9, 2018: Current Medicinal Chemistry
Eiji Kutoh, Jyunka Hayashi
This report describes the effect of administration (n=3) or withdrawal (n=2) of canagliflozin, a sodium-glucose co-transporters 2 (SGLT-2) inhibitor, on cardiac function in relation to ketone bodies. Three cases received and two cases discontinued canagliflozin. Changes of heart function with ultrasonography (EF: ejection fraction and %FS: functional shortening) and cardiometabolic parameters including ketone bodies (acetoacetate/beta-hydroxybutylate) were compared at 3 months. 69, 68 and 60 years old male patients A, B and C, respectively with moderately decreased heart function received canagliflozin 100 mg/day...
October 8, 2018: Drug Research
Sruthi Adimadhyam, Glen T Schumock, Gregory S Calip, Daphne E Smith Marsh, Brian T Layden, Todd A Lee
AIM: To determine the risk of mycotic infections associated with the use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in a real world setting. METHODS: We conducted a prescription sequence symmetry analysis (PSSA) using data from Truven Health MarketScan® (2009-2015). We selected continuously enrolled patients newly initiating both an SGLT2i and an antifungal between 1st April, 2013 and 31st December, 2015 within 'time periods' of 30,60,90,180, or 365 days of each other...
October 7, 2018: British Journal of Clinical Pharmacology
Kwong-Man Ng, Yee-Man Lau, Vidhu Dhandhania, Zhu-Jun Cai, Yee-Ki Lee, Wing-Hon Lai, Hung-Fat Tse, Chung-Wah Siu
Empagliflozin, a sodium-glucose co-transporter (SGLT) inhibitor, reduces heart failure and sudden cardiac death but the underlying mechanisms remain elusive. In cardiomyocytes, SGLT1 and SGLT2 expression is upregulated in diabetes mellitus, heart failure, and myocardial infarction. We hypothesise that empagliflozin exerts direct effects on cardiomyocytes that attenuate diabetic cardiomyopathy. To test this hypothesis, cardiomyocytes derived from human induced pluripotent stem cells (hiPSCs) were used to test the potential effects of empagliflozin on neutralization of cardiac dysfunction induced by diabetic-like cultures...
October 5, 2018: Scientific Reports
Christopher P Cannon, Darren K McGuire, Richard Pratley, Sam Dagogo-Jack, James Mancuso, Susan Huyck, Bernard Charbonnel, Weichung J Shih, Silvina Gallo, Urszula Masiukiewicz, Gregory Golm, Francesco Cosentino, Brett Lauring, Steven G Terra
BACKGROUND: Ertugliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), approved in the United States and European Union to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). The VERTIS cardiovascular (CV) outcomes trial (NCT01986881) has a primary objective to demonstrate non-inferiority of ertugliflozin versus placebo on major adverse CV events: time to the first event of CV death, nonfatal myocardial infarction, or nonfatal stroke. Secondary objectives are to demonstrate superiority of ertugliflozin versus placebo on time to: 1) the composite outcome of CV death or hospitalization for heart failure (HF); 2) CV death; and 3) the composite outcome of renal death, dialysis/transplant, or doubling of serum creatinine from baseline...
September 5, 2018: American Heart Journal
Ayumi Kanno, Shun-Ichiro Asahara, Mao Kawamura, Ayuko Furubayashi, Shoko Tsuchiya, Emi Suzuki, Tomoko Takai, Maki Koyanagi-Kimura, Tomokazu Matsuda, Yuko Okada, Wataru Ogawa, Yoshiaki Kido
AIMS/INTRODUCTION: The preservation of pancreatic β-cell mass is an essential factor in the onset and development of type 2 diabetes mellitus. Recently, sodium-glucose co-transporter 2 inhibitors have been launched as anti-hyperglycemic agents, and their organ-protective effects are attracting attention. They are also reported to have favorable effects on the preservation of pancreatic β-cell mass, but the appropriate timing for the administration of sodium-glucose co-transporter 2 inhibitors is obscure...
October 5, 2018: Journal of Diabetes Investigation
Sara B Seidelmann, Elena Feofanova, Bing Yu, Nora Franceschini, Brian Claggett, Mikko Kuokkanen, Hannu Puolijoki, Tapani Ebeling, Markus Perola, Veikko Salomaa, Amil Shah, Josef Coresh, Elizabeth Selvin, Calum A MacRae, Susan Cheng, Eric Boerwinkle, Scott D Solomon
BACKGROUND: Loss-of-function mutations in the SGLT1 (sodium/glucose co-transporter-1) gene result in a rare glucose/galactose malabsorption disorder and neonatal death if untreated. In the general population, variants related to intestinal glucose absorption remain uncharacterized. OBJECTIVES: The goal of this study was to identify functional SGLT1 gene variants and characterize their clinical consequences. METHODS: Whole exome sequencing was performed in the ARIC (Atherosclerosis Risk in Communities) study participants enrolled from 4 U...
October 9, 2018: Journal of the American College of Cardiology
Nadine Schäfer, Maximilian Friedrich, Morten Egevang Jørgensen, Sina Kollert, Hermann Koepsell, Erhard Wischmeyer, Klaus-Peter Lesch, Dietmar Geiger, Frank Döring
Sodium-glucose transporters (SGLT) belong to the solute carrier 5 family, which is characterized by sodium dependent transport of sugars and other solutes. In contrast, the human SGLT3 (hSGLT3) isoform, encoded by SLC5A4, acts as a glucose sensor that does not transport sugar but induces membrane depolarization by Na+ currents upon ligand binding. Whole-exome sequencing (WES) of several extended pedigrees with high density of attention-deficit/hyperactivity disorder (ADHD) identified a triplet ATG deletion in SLC5A4 leading to a single amino acid loss (ΔM500) in the hSGLT3 protein imperfectly co-segregating with the clinical phenotype of ADHD...
2018: PloS One
Kazuo Kobayashi, Masao Toyoda, Moritsugu Kimura, Nobuo Hatori, Takayuki Furuki, Hiroyuki Sakai, Masahiro Takihata, Tomoya Umezono, Shun Ito, Daisuke Suzuki, Hiroshi Takeda, Akira Kanamori, Hisakazu Degawa, Hareaki Yamamoto, Hideo Machimura, Atsuko Mokubo, Keiichi Chin, Mitsuo Obana, Toshimasa Hishiki, Kouta Aoyama, Shinichi Nakajima, Shinichi Umezawa, Hidetoshi Shimura, Togo Aoyama, Kazuyoshi Sato, Masaaki Miyakawa
AIM: The aim of this study was to assess the renal effects of the glucose-lowering SGLT2 inhibitors in Japanese type 2 diabetes mellitus patients with chronic kidney disease. METHODS: The Kanagawa Physicians Association maintains a registry of patients who visit their 31 clinics. Clinical data of type 2 diabetes mellitus patients with chronic kidney disease, who were prescribed SGLT2 inhibitors in addition to other treatments, were collected and analysed. RESULTS: SGLT2i was associated with a fall in HbA1c from 64...
October 4, 2018: Diabetes & Vascular Disease Research
Sonia Rocha, Daniela Ribeiro, Eduarda Fernandes, Marisa Freitas
The use of anti-diabetic drugs has been increasing worldwide and the evolution of therapeutics has been enormous. Still, the currently available anti-diabetic drugs do not present the desired efficacy and are generally associated with serious adverse side effects. Thus, entirely new interventions, addressing the underlying etiopathogenesis of type 2 diabetes mellitus, are required. Chalcones, secondary metabolites of terrestrial plants and precursors of the flavonoids biosynthesis, have been used for a long time in the traditional medicine due to their wide-range of biological activities, from which the anti-diabetic activity stands out...
October 1, 2018: Current Medicinal Chemistry
Lei Zhang, Shiew-Mei Huang, Kellie Reynolds, Rajanikanth Madabushi, Issam Zineh
Transporters can affect a drug's pharmacokinetics (PK) by controlling absorption, distribution, and elimination processes. They can also affect a drug's pharmacodynamics (PD) by influencing its access to the site of action. More recently, transporters have become important as drug targets (e.g., urate transporter inhibitors as treatment for gout and sodium/glucose cotransporter-2 inhibitors for treating type 2 diabetes). As such, it is important to consider the role of transporters during drug development.
September 30, 2018: Clinical Pharmacology and Therapeutics
Shivraj S Riar, David Fitchett, Jeremy FitzGerald, Payam Dehghani
Cardiovascular mortality is the primary cause of death in patients with type 2 diabetes mellitus (T2DM). Recently, clinical trials of the sodium-glucose transport protein 2 (SGLT-2) inhibitors empagliflozin and canagliflozin and of the glucagon-like peptide-1 (GLP-1) agonists liraglutide and semaglutide demonstrated that the agents reduced cardiovascular events. Furthermore, empagliflozin and liraglutide reduced cardiovascular mortality. However, despite the proven cardiac benefits, many but not all provincial formularies have restrictive rules for payment and access for SGLT-2 inhibitors and GLP-1 agonists...
October 2018: Canadian Journal of Cardiology
Guozhang Xu, Michael D Gaul, Gee-Hong Kuo, Fuyong Du, June Zhi Xu, Nathaniel Wallace, Simon Hinke, Thomas Kirchner, Jose Silva, Norman D Huebert, Seunghun Lee, William Murray, Yin Liang, Keith Demarest
A new series of (2S,3R,4R,5S,6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3,4-diols as dual inhibitors of sodium glucose co-transporter proteins (SGLTs) were disclosed. Two methods were developed to efficiently synthesize C5 -fluoro-lactones 3 and 4, which are key intermediates to the C5 -fluoro-hexose based C-aryl glucosides. Compound 2b demonstrated potent hSGLT1 and hSGLT2 inhibition (IC50  = 43 nM for SGLT1 and IC50  = 9 nM for SGLT2). It showed robust inhibition of blood glucose excursion in oral glucose tolerance test (OGTT) in Sprague Dawley (SD) rats and exerted pronounced antihyperglycemic effects in db/db mice and high-fat diet-fed ZDF rats when dosed orally at 10 mg/kg...
September 19, 2018: Bioorganic & Medicinal Chemistry Letters
Jo-Anne E Manski-Nankervis, Sharmala Thuraisingam, Janet K Sluggett, Phyllis Lau, Irene Blackberry, Jenni Ilomaki, John Furler, J Simon Bell
AIM: To determine whether the prescribing of non-insulin anti-hyperglycaemic medications in Australian general practice is consistent with current guidelines for treatment of type 2 diabetes (T2D) in people with renal impairment. METHODS: Cross-sectional study of 9624 people with T2D in the NPS MedicineInsight dataset aged≥18years with average estimated glomerular filtration rate (eGFR) <60ml/min/1.73m2 and prescribed at least one non-insulin anti-hyperglycaemic medication from October 2014 to September 2015...
September 24, 2018: Primary Care Diabetes
Keke Wang, Yansong Zhang, Chunyang Zhao, Mingyan Jiang
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors and dipeptidyl peptidase 4 (DPP-4) inhibitors are both novel and second-line therapies in type 2 diabetes mellitus, yet no well-rounded comparison of these two drugs has been published. Upon searching randomized controlled trials in databases from inception to July 2018, we collected studies on the efficacy or safety of SGLT-2 inhibitors compared with those of DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. A total of 12 randomized controlled studies including 4342 patients were included in this meta-analysis...
October 2018: Hormone and Metabolic Research, Hormon- und Stoffwechselforschung, Hormones et Métabolisme
Partha Choudhury, Manoj Gupta
The term theranostics is the combination of a diagnostic tool that helps to define the right therapeutic tool for specific disease. It signifies the "we know which sites require treatment (diagnostic scan) and confirm that those sites have been treated (post therapy scan)" demonstrating the achievable tumor dose concept. This term was first used by John Funkhouser at the beginning of the 90's at the same time the concept of personalized medicine appeared. In nuclear medicine theranostics is easy to apply and understand because of an easy switch from diagnosis to therapy with the same vector...
September 27, 2018: British Journal of Radiology
Muhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, Rajvir Singh, Mohammad Fawaz, Ralph A DeFronzo, Amin Jayyousi
Because of the unique mechanism of action of sodium-glucose co-transport inhibitors (SGLT2i), which is independent of insulin secretion and insulin action, members of this class of drugs effectively lower plasma glucose concentration when used in combination with all other antidiabetic agents, including insulin. Increased plasma ketone concentration has been reported in association with SGLT2i initiation, which under certain clinical conditions has developed into diabetic ketoacidosis. The daily insulin dose often is reduced at the time of initiating SGLT2i therapy in insulin-treated patients to avoid hypoglycemia...
September 26, 2018: Diabetes, Obesity & Metabolism
Nikhil Bassi, Gregg C Fonarow
PURPOSE OF REVIEW: Type 2 diabetes mellitus (DM) is a major risk factor for the development of heart failure (HF). In patients with DM, preventing HF using diabetes medications should be an imperative for primary care physicians and cardiologists alike. RECENT FINDINGS: Prior studies with DPP-IV inhibitors, thiazolidinediones (TZDs), and GLP-1 agonists have demonstrated either a neutral effect on HF or increased HF hospitalizations. Two recent large-scale randomized controlled trials (RCTs), EMPA-REG OUTCOME and CANVAS, compared sodium glucose transporter-2 inhibitor (SGLT-2i) to placebo...
September 26, 2018: Current Cardiology Reports
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"